XPC and female reproductive system neoplasm: Among these 31 patients, 2 are XP-V (6.5%) and 29 are XP-C (93.5%) among which 28 (90%) originated from North Africa, and carry the XPC delTG mutation: 59% are hematological malignancies, 17% gynecological tumors, 10% THY tumors and 10% CNS tumors (Table 1).